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Review
The pathogenesis of tendinopathy.
A molecular perspective
G. Riley
There are many publications that discuss the aetiology, diagnosis
and treatment of the various forms of tendinopathy, but few
are based on conclusive scientiﬁc evidence. The pathogenesis of
tendinopathy is difﬁcult to study because tendon biopsies are rarely
obtained before a tendon has ruptured. There are interesting
comparisons with animal tendinopathy, particularly in the equine
athlete, although many animal models do not accurately reﬂect the
human condition—the tendon lesions usually heal. However, the
application of biochemical and molecular techniques to the study
of both animal and human tendinopathy has led to a greater
understanding of these common and disabling conditions.
This article summarizes current knowledge of the pathogenesis
of tendinopathy, with particular emphasis on the molecular
pathology of the tendon matrix.
Classiﬁcation and terminology
Tendons may be affected by a variety of different pathological
conditions. Many systemic diseases are associated with general
defects in matrix metabolism and structure that compromise
tendon strength and elasticity, or result in inﬂammation of the
tendon or its insertion [1–3] (Table 1). These conditions are not the
subject of this review, although they must be considered as part of
the differential diagnosis.
Tendonitis (or tendinitis) is the term traditionally used to
describe a chronic painful tendon, and assumes that tendon injury
is accompanied by an inﬂammatory response. This is contrary to
the evidence from histopathological, biochemical and molecular
studies, and the lesion is perhaps better described as a ‘tendinosis’
[4–9]. However, as we cannot exclude the possibility that
inﬂammation is implicated at some stage in the condition, the
term ‘tendinopathy’ is used throughout this article to describe
disorders primarily affecting tendons, including tendon rupture
and chronic pain. Unlike tendonitis and tendinosis, this term does
not assume any knowledge about the underlying pathology.
Another term in frequent use is ‘spontaneous tendon rupture’,
used to describe ruptures that occur without any preceding clinical
symptoms [5, 10]. Because healthy tendons can withstand very
high tensile loads—much higher than required for their normal
function—these conditions are rarely truly spontaneous and are
associated with at least some degree of matrix degeneration [10, 11].
The precise nature of the degenerative process is still the matter of
debate. There are a variety of degenerative features associated with
tendinopathy, including glycosaminoglycan (GAG) accumulation,
calciﬁcation and lipid accumulation. However, many of these
features are found in normal tendons and are not necessarily
pathological [5, 6, 12–14].
Aetiology of tendinopathy
Tendinopathy can be associated with a variety of both intrinsic and
extrinsic factors (Table 2). High body mass and constitutional
factors such as leg-length discrepancies can place tendons under
excessive or abnormal patterns of loading [15, 16]. A sedentary
lifestyle allied with the particular physical demands of occupation
or sporting activities may account for the increased incidence of
tendon rupture in recent times. The inﬂuence of an individual’s sex
and genetic background is unknown, although some association
with genetic factors has been postulated in a proportion of patients
[15, 17]. Laxity of the joints may be a predisposing factor for patella
tendinopathy and rotator cuff lesions [15]. Gene defects affecting
tendon (collagen) ﬁbre formation and metabolism may explain
some of these conditions, although as yet no defect has been
identiﬁed that is speciﬁcally associated with tendinopathy [1].
The literature is dominated by two hypotheses on the cause of
tendon rupture—a mechanical theory and a vascular theory—but
the two are not mutually exclusive. Many lesions are associated
with low or reduced vascular perfusion in tendons such as the
supraspinatus and Achilles [15, 18–21]. A decrease in circulation
may occur as a result of ageing, vascular disease, physical disuse or
trauma, leading to tissue hypoxia and reduced viability of the
tendon cells. However, in apparent contradiction of this theory,
chronic tendon lesions often show an increase in vascularity and
increased cellularity [6, 13], a so-called angioﬁbroblastic response
[22], and there is an increase in the tendon blood ﬂow [23, 24].
Whether this represents evidence of a healing response, secondary
to the initial lesion, is uncertain [24].
Many painful tendon lesions are thought to be the result of
repetitive microtrauma, frequently described as ‘overuse’ pathol-
ogies [16, 25–28]. This is often explained with reference to the
biomechanical properties of tendon and the stress–strain curve [29]
(Fig. 1). Physiological loads usually cause less than a 4% increase
in the length of the tendon [26, 30]. Strain above 4% results in
damage to one or more of the tendon ﬁbre bundles, and strains in
excess of 8–12% result in complete tendon rupture. Most overuse
tendinopathy is associated with repeated microstrain below the
failure threshold, analogous to the fatigue failure that affects most
materials placed under repetitive loading. It is generally assumed
that tendon matrix damage is the primary event, overwhelming the
ability of the resident cell population to repair structural defects.
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Because cell activity is required for the maintenance of connective
tissues, it is equally possible that changes in cell metabolism—more
speciﬁcally, the synthesis and degradation of the extracellular
matrix—can inﬂuence the structural properties of the tendon.
In other words, changes in cell activity in response to mechanical
strain may be primary and not secondary to any physical lesion or
‘micro-injury’.
It is now recognized that most tendinopathy is rarely associated
with any single factor, and the degenerative process that precedes
tendon rupture may result from a variety of different pathways and
causative factors. Indeed, there is some evidence to suggest that the
nature of the degenerative process varies among different sites [5].
Many questions remain about the role of tendon ﬁbroblasts
(tenocytes) and other cell types in the disease process. In the
absence of an overt inﬂammatory process, there is no rational basis
for the use of anti-inﬂammatories in chronic tendinopathy, and the
source of tendon pain is not understood [31–33]. An objective
approach to the treatment of tendinopathy requires a greater
knowledge of the tendon matrix and its changes in health and
disease.
Structure of tendon
The structure, composition and organization of the matrix are
critically important for the physical properties of tendon. The
smallest structural unit is the ﬁbril, largely consisting of rod-like
collagen molecules aligned end-to-end in a quarter-staggered array
[34–36] (Fig. 1A). The ﬁbrils range in diameter from 10 to 500 nm
depending on the age, location and species from which the tendon
is sampled [37–40]. One or more distinct ﬁbril populations are
normally present: a single population of small diameter ﬁbrils in
young animals, and a bimodal distribution of small and large
diameter ﬁbrils in mature animals [38, 39, 41].
Collagen ﬁbrils aggregate together into ﬁbres, and bundles of
ﬁbres (‘fascicles’) are bound together by a thin layer of loose
connective tissue known as the endotenon [34] (Fig. 1B). The
endotenon carries blood vessels, lymphatics and nerves which
generally pass up and down throughout the body of the tendon
[34, 42]. Bundles of fascicles are surrounded by the epitenon, a
structure contiguous with the endotenon and also relatively rich
in blood vessels, lymphatics and nerves [34]. Fibre bundles are
predominantly aligned with the long axis of the tendon and
these are responsible for the tensile strength of the tendon. A small
proportion of ﬁbres run transversely, and there are even
spirals and plait-like formations [40, 43]. This complex ultrastruc-
ture provides resistance against transverse, shear and rotational
forces acting on the tendon.
The size of the ﬁbre bundles is related to the macroscopic size
and function of the tendon, with small fascicles generally found in
digital tendons and large fascicles in big, weight-bearing tendons
such as the Achilles [40]. The fascicular structure is thought to
provide a fail-safe mechanism, so that failure of one or a few ﬁbre
bundles does not signiﬁcantly reduce the strength of the whole
tendon. Fibre bundles commonly exhibit a planar zigzag or ‘crimp’,
best seen when longitudinal sections are viewed under polarized
light [44] (Fig. 1C). The stretching out of the crimp accounts for the
‘toe’ region of the tendon stress–strain curve, which acts as a buffer
against ﬁbre damage [29] (Fig. 1D). The angle and length of crimp
can vary in different tendons and at different sites within a tendon
[45]. This has implications for the mechanical properties of the
tissue, as ﬁbres with a small crimp angle will fail before those with
a larger crimp angle [45].
TABLE 1. Systemic diseases affecting tendon
Disease Structural defect or effect on tendon
Inherited disorders
Ochronosis (homocystinuria) Deﬁcient collagen and elastin cross-linking
Aspartylglycosaminuria (AGU) Abnormal collagen/deﬁcient cross-linking?
Haemochromatosis Accumulation of iron in matrix
Menkes kinky hair syndrome Defect in collagen and elastin cross-linking
Mucopolysaccharidoses Abnormal collagen ﬁbrils, increased GAG
Marfan syndrome Abnormal ﬁbril structure
Ehlers–Danlos syndromes Various defects in collagen processing and structure
Osteogenesis imperfecta Genetic defects in type I collagen
Lipid storage diseases Xanthomas: slow growing lipid deposits
Myopathies and dystrophies Abnormal ﬁbril structure
Endocrine and metabolic diseases
Diabetes mellitus Increased glycation and cross-linking of collagen
Adrenal disorders Altered collagen metabolism
Thyroid disorders Calciﬁcation and accumulation of deposits
Amyloidosis Accumulation of deposits between ﬁbrils
Renal disease Elastosis, destruction of collagen ﬁbres
Rheumatological diseases
Rheumatoid arthritis Destruction of collagen: inﬂammatory inﬁltrate
Spondylarthropathies Inﬂammation at insertion, ﬁbrosis and calciﬁcation
Reactive arthritis Inﬂammation at insertion
Reiter’s syndrome Inﬂammation at insertion
Gout Urate crystal deposits and inﬂammation
Pseudogout Calcium pyrophosphate deposits and inﬂammation
TABLE 2. Factors implicated in chronic tendinopathy
Intrinsic factors Extrinsic factors
Age Occupation
Vascular perfusion Sport
Nutrition Physical load
Anatomical variants Excessive force
Leg-length discrepancy Repetitive loading
Mal-alignments
(e.g. genu valgum)
Abnormal/unusual movement
Training errors
Bony impingement
(e.g. acromion)
Poor technique
Fast progression
Joint laxity High intensity
Muscle weakness/imbalance Fatigue
Gender (?) Shoes and equipment
Body weight Environmental conditions
Systemic disease Temperature
Running surface
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Collagens in tendon
Although type I collagen constitutes around 60% of the dry mass
of the tissue and approximately 95% of the total collagen [46–48],
the ﬁbrils are actually composites of several different collagens,
proteoglycans and glycoproteins [49]. Type III collagen is the next
most abundant collagen, constituting around 3% of the total in
human supraspinatus and biceps brachii tendons [48]. In normal
tendons, type III collagen tends to be restricted to the endotenon
and epitenon [50]. However, it is also found intercalated into type I
collagen ﬁbrils, particularly in ageing tendons and at the insertion
sites of highly stressed tendons such as the supraspinatus [51]. As
type III collagen tends to produce smaller, less organized ﬁbrils
[52], this has implications for the mechanical strength of the
tendon. Type V collagen is intercalated into the core of the type I
collagen ﬁbril, where it forms a template for ﬁbrillogenesis and
modulates ﬁbril growth [53, 54]. Type IV collagen, which forms
a meshwork structure, is restricted to the basement membrane of
the tendon blood vessels [47]. Type VI collagen forms sheet-like
structures and is usually found co-distributed with type I collagen
ﬁbres in normal tendon [47, 55]. There is a different distribution in
tendon ﬁbrocartilage at the insertion, where type VI collagen is
predominantly cell-associated, as it is in cartilage [55]. Type XII
and type XIV collagens are associated with the surface of the type I
collagen ﬁbrils, particularly at the insertion [56]. These collagens
are FACITs (ﬁbril-associated collagens with interrupted triple
helix), with relatively large non-helical domains that are thought to
mediate interactions with other matrix components. Other
collagens found in small quantities in tendon include types II,
IX, X and XI [57]. Once thought to be restricted to cartilage, these
collagens are found in the ﬁbrocartilage at the bone insertion,
where they are may function to dissipate stress concentration at
the hard tissue interface [55, 57].
FIG. 1. The structure and physical properties of tendon. (A) Collagen (type I) forms rod-like molecules which spontaneously associate
with other molecules to form a quarter-staggered array. The overlap and hole zones account for the characteristic banded ﬁbril seen
using the electron microscope, due to the differential uptake of electron-dense stains. (B) Bundles of ﬁbrils form ﬁbres, the ﬁbres are
bound together by a thin layer known as endotenon, and several ﬁbre bundles are surrounded by an outer layer known as the
epitenon. (C) Haemotoxylin and eosin-stained section of normal tendon showing the wave or crimp pattern of the collagen ﬁbres. (D)
When strain is applied to a tendon, there is ﬁrst a straightening out of the crimp, resulting in the ‘toe region’ of the stress–strain curve.
Strain within the physiological range causes elastic deformation of the tendon. Higher levels of strain result in partial or complete
rupture of ﬁbrils. Actual levels of strain required to induce tendon damage differ in different tendons and are affected by factors such
as age and cross-linking of the matrix. This ﬁgure can be viewed in colour as supplementary material at Rheumatology Online.
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Collagens in the matrix are stabilized by the formation of cross-
links [58, 59]. Some cross-links are formed between adjacent amino
acids after modiﬁcation by the enzyme lysyl oxidase. Initially,
reducible cross-links are formed between two amino acids [59]. As
the tissue ages, these combine with another adjacent amino acid to
form mature trifunctional cross-links. Not all of the mature cross-
links have been identiﬁed, although the best-characterized are
hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). LP,
otherwise known as deoxypyridinoline, is essentially restricted to
bone and is present only in small quantities in soft connective
tissues [59–61].
The amount of HP in a given connective tissue is related to its
mechanical function, with the highest concentration in hyaline
cartilage and intervertebral discs, which contain approximately
twoHP cross-links per collagen molecule [58]. Tendons have a high
HP content compared with other soft tissues, although there are
substantial differences between tendons. For example, human
supraspinatus tendons had over three times the HP content of
biceps brachii tendons (0.81 and 0.25 HP cross-links per collagen
molecule respectively), presumably reﬂecting the different mechan-
ical demands placed on these tendons [61]. A greater concentration
of HP is generally found in compressed tendons, associated with
the ﬁbrocartilaginous composition found at these sites [62–64].
However, the HP content does not change signiﬁcantly after
skeletal maturity, and these cross-links probably do not contribute
to the altered physical properties of ageing tendons [61].
Another form of collagen cross-linking occurs by the process of
non-enzymic glycation. Reducing sugars such as pentose derived
from the circulation bind irreversibly to long-lived proteins in the
matrix [59, 65]. There are no enzymes involved, and sugars attach
throughout the length of the collagen molecule. Over time,
Amadori rearrangement results in the formation of irreversible
cross-links between adjacent sugars, creating Maillard browning
products, perhaps better known as advanced glycation end-
products (AGEs). AGEs are responsible for many of the altered
physical and chemical properties of ageing tissues, such as the
reduction in elasticity and decreased solubility. They also have an
effect on cell–matrix interactions in the tissue, a possible cause of
some of the altered cell activities seen in diseases of ageing, such as
osteoarthritis [66, 67]. Although there are a variety of AGEs, the
best characterized is the naturally ﬂuorescent cross-link known as
pentosidine [68]. Because the turnover of matrix proteins such as
collagen is generally very low, AGEs such as pentosidine accu-
mulate gradually on collagen molecules with age. Consequently,
the pentosidine content serves as a marker of the molecular age
of the tissue, and this property has been exploited in recent studies
of the tendon matrix [61] (see below).
Proteoglycans in tendon
Proteoglycans are a heterogeneous group of proteins with many
different functions in the matrix, although all usually carry at least
one side-chain of GAG, a complex sugar moiety of repeating
disaccharides [69]. In the tension-bearing regions of a bovine ﬂexor
tendon, proteoglycans constitute between 0.2 and 0.5% of the
tendon dry weight [70]. The most abundant proteoglycan is
decorin, and there are small amounts of biglycan [71]. Small
proteoglycans represented almost 90% of the total, and the
remainder was a large proteoglycan, thought to be a processed
form of aggrecan (lacking the G1 domain) rather than versican
[72]. In weight-bearing regions of bovine ﬂexor digitorum
profundus tendons, the proteoglycan content was around 3.5%
of the tendon dry weight, with a high content of aggrecan and
biglycan [62, 70]. A similar proteoglycan composition has been
described in ﬁbrocartilaginous regions of rabbit and dog tendons
[73, 74]. The accumulation of aggrecan occurs after weight-bearing
in the neonate, and the maintenance of synthesis is dependent
on compressive load [75]. The ﬁbrocartilage at these sites is a
protective adaptation, the aggrecan holding water within the tissue
and acting to resist compression [62].
Regional differences in tendon morphology and composition
have been identiﬁed in human tendons [55, 63, 76, 77]. In Achilles
tendons, decorin, biglycan, lumican and ﬁbromodulin were
identiﬁed in both ﬁbrocartilaginous and tension-bearing regions,
at both the mRNA and the protein level [55]. Versican was the
major large proteoglycan in the tendon mid-substance, with lesser
amounts of aggrecan. In contrast, the ﬁbrocartilage of the Achilles
insertion contained mainly aggrecan with lesser amounts of
versican.
Site-speciﬁc variations in proteoglycan content are related to
the mechanical history and function of the tendon. Tendons of the
short head of biceps brachii contain around 0.2%proteoglycan, the
majority carrying dermatan sulphate GAG side chains (80%)
and the remainder chondroitin sulphate, consistent with a pre-
dominance of decorin in ﬂexor tendons, which experience mainly
tensile loads [63]. Substantially higher levels of proteoglycan are
found in supraspinatus tendons, mainly chondroitin sulphate with
lesser amounts of dermatan sulphate and keratan sulphate [63].
These proteoglycans have since been characterized, conﬁrming that
aggrecan is the major large proteoglycan, together with signiﬁcant
amounts of biglycan [64]. This ﬁbrocartilaginous composition is
thought to be a result of adaptive metaplasia to the compressive
load experienced by the supraspinatus tendon in the rotator cuff,
which wraps around the head of humerus and may experience
impingement from the overlying bone and ligament.
Similar ﬁbrocartilaginous regions have also been described in
human peroneus, tibialis and extensor digitorum tendons [76, 77].
Although thought to be a protective adaptation, the formation of
ﬁbrocartilage may have pathological signiﬁcance, modifying the
structural properties and affecting the tendon response to injury,
for example. Autoimmune reactions against cartilaginous con-
stituents of ﬁbrocartilage may also explain why tendon insertions
are prone to inﬂammation in the spondylarthropathies.
Ageing of the tendon matrix
Age affects the tendon matrix in a variety of ways. During
maturation, the cell density decreases dramatically and there is a
corresponding increase in collagen content and a decrease in
glycosaminoglycan content [30, 78]. The collagen cross-link proﬁle
changes from immature, difunctional cross-links to mature,
trifunctional cross-links. After maturity, there is no signiﬁcant
change in the total collagen concentration, which remains
predominantly type I collagen [48]. However, the distribution of
minor collagens, such as type III, may change, with a greater
proportion incorporated into the type I ﬁbres [48]. Collagen ﬁbre
bundles tend to become larger, the thermal stability increases and
the tendon becomes stiffer and less elastic [39, 79, 80]. There is a
substantial decrease in the solubility of collagen, thought to be
associated with the accumulation of AGE cross-links, such as
pentosidine [81]. Some of these changes may be counteracted by
exercise, although there is some evidence that mature tendons have
little capacity for adaptation and are damaged by exercise [82].
There is evidence of accumulated physical damage in ageing
tendons, with increases in the amount of denatured collagen and
increased proteolytic cleavage of matrix components [86]; these
changes are all associated with deterioration in the physical
properties of the tendon. Age is commonly associated with
increased prevalence of degenerative changes, such as lack of ﬁbre
organization, decreased cellularity and increased GAG content
[6, 12]. However, degeneration is not an inevitable consequence of
ageing, because other tendons may be unaffected [14]. Tendons
from particular sites, such as the shoulder, elbow, knee and ankle,
are most likely to show degenerative changes, which increase in
severity with age and are associated with the high physical demands
placed upon the tendons at these joints [20, 83].
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Matrix turnover in tendon
Matrix turnover, involving both the synthesis and degradation of
matrix components, is important for the maintenance and repair
of all connective tissues, and tendon is no exception. Once thought
of as inert and incapable of participating in repair, tenocytes
have been shown to be active throughout the lifespan, express-
ing a variety of matrix proteins and matrix-degrading enzymes
[9, 84–86]. However, differences between tendons from different
sites and regional variations within tendons may be important in
tendon disease, as discussed in more detail below.
Some studies have investigated the effects of exercise on Achilles
tendon collagen turnover, using microdialysis catheters inserted
into the peritendinous space [87–89]. Vigorous exercise induced
increased formation of type I collagen, measured by procollagen
peptide analysis of the dialysate 72 h after exercise [87]. There was a
decrease in the rate of collagen degradation during the early
recovery phase, but no signiﬁcant difference from controls at 72 h.
Thus, exercise was shown to induce anabolic, adaptive processes in
the human Achilles tendon, at least in trained individuals. The
training effect was further demonstrated in a later study, which
showed an increased rate of turnover of collagen (both synthesis
and degradation) after 4 weeks of training, but predominantly
anabolic effects after 11 weeks of training [89].
Similar studies have shown that exercise increases the
peritendinous levels of various mediators of vasodilation and
inﬂammation, such as bradykinin, adenosine, interleukin (IL) 6,
thromboxane and prostaglandin E2 [87, 90–93]. There was also a
two-fold increase in lactate and glycerol, demonstrating changes in
lipid and carbohydrate metabolism as well as inﬂammatory activity
after short bouts of exercise [90]. These activities are presumably
implicated in the adaptive response of tendon, although excessive
stimulation of some or all of these factors may conceivably have a
role in the onset of tendinopathy as a result of overuse (see below).
Collagen degradation in tendon
Collagen type I is relatively resistant to enzymatic degradation, and
once laid down and cross-linked into the matrix it has a long half-
life [94]. Consequently, with age the collagen becomes increasingly
glycated, and the AGE cross-link pentosidine accumulates,
forming a useful marker of the protein residence time [94, 95].
In the biceps brachii tendon, pentosidine accumulates in a linear
fashion with age, consistent with low levels of collagen turnover in
this tendon [61] (Fig. 2). Pentosidine does not accumulate at the
same rate in ageing supraspinatus tendons, indicating relatively
high levels of collagen turnover [61, 86]. The increased rate of
turnover compared with the biceps tendon is thought to be
associated with the high levels of strain normally experienced by
supraspinatus tendons in everyday use. The enzymes responsible
for this activity are consequently particularly important, as
inappropriate or excessive matrix turnover is a likely cause of the
matrix damage in tendinopathy.
Some collagen in tendon is probably degraded intracellularly
after phagocytosis, with ﬁbroblasts and macrophages engulﬁng
collagen molecules which are then digested by lysosomal enzymes
[96, 97]. This is a major activity in the rapidly remodelling
peridontal ligament, although few studies have investigated the
relative importance of this route in tendon. Most studies have
focused on collagen degradation occurring in the extracellular
environment and mediated by secreted proteases.
Collagenases, members of the matrix metalloproteinase (MMP)
superfamily, are some of the few enzymes capable of cleaving the
intact type I collagen molecule in the extracellular environment
[98–100]. Cleavage occurs at a speciﬁc locus in the collagen triple
helix, between residues 775 and 776 [99], and is the rate-limiting
step in (ﬁbrillar) collagen turnover, generating three-quarter- and
one-quarter-length fragments that are in turn susceptible to other
proteinases, such as the gelatinases. MMPs with collagenase
activity include MMP-1 (collagenase-1, EC 3.4.24.7), MMP-8
(neutrophil collagenase, EC 3.4.24.34) and MMP-13 (collagen-
ase-3, MEROPS ID M10.013) as well as the gelatinase MMP-2
(gelatinase A, EC 3.4.24.24) and the membrane-type MMP-14
(MT1-MMP, MEROPS ID M10.014). The collagenases differ in
their activities against the various ﬁbrillar collagens [101], although
precisely which enzymes are implicated in the physiological and
pathological turnover of connective tissue is still the subject of
extensive research.
Studies of tendon in explant culture have shown that MMP-1 is
released into the culture medium and associated with the collagen
breakdown that occurs usually after 14–21 days in culture [102,
103]. An extended culture period is required, possibly because
FIG. 2. Tendon pentosidine content, a marker of matrix age. (A)
The AGE product pentosidine accumulates in a linear fashion
with increasing age in the human biceps brachii tendon. These
tendons were histologically normal, and the data are consistent
with very low levels of matrix (collagen) turnover throughout the
lifespan. (B) There is a very poor relationship of pentosidine
content with age in the human supraspinatus tendon. Although
there was no history of shoulder pathology, some evidence of
degenerative change in the tendon was common. The pentosidine
content demonstrates that much of the mature glycated collagen
network has been replaced during an individual’s life. Data from
Bank et al. [61].
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removal of the proteoglycan component from around the collagen
ﬁbril is a prerequisite for collagen degradation. Breakdown can be
stimulated by the inﬂammatory cytokine IL-1 and potentiated by
the cytokine oncostatin M, and is associated with increased
MMP-1 activity and reduced levels of TIMP-1 (tissue inhibitor of
metalloproteinases) in the media [103]. Factors that regulate
enzyme activities in tendon are consequently likely to have a role in
tendinopathy, as discussed in more detail below.
Proteoglycan degradation in tendon
Proteoglycans are turned over much more rapidly than the ﬁbrillar
collagens. Although some members of the MMP family, such as
MMP-3 (stromelysin 1), can degrade proteoglycans such as
aggrecan in vitro, most activity in vivo is associated with a related
but distinct group of metallo-endopeptidases commonly known as
‘aggrecanases’.
Aggrecanases were recently identiﬁed as members of the
ADAMTS family, a subgroup of ADAM (a disintegrin and
metalloproteinase) with thrombospondin (TS) type I motifs [104].
The TS domains bind to GAG and may function to sequester
aggrecanases in the matrix. ADAMTS-4 (aggrecanase 1) and
ADAMTS-5 (aggrecanase 2) both cleave aggrecan at a speciﬁc
locus, between residues Glu[373] and Ala[374] in the interglobular
domain of the core protein [104–106]. ADAMTS-1 can also
degrade aggrecan at the same locus in vitro, and may be a
third aggrecanase [107]. ADAMTS-4 also has activity against
the brain-speciﬁc proteoglycan brevican [108], although little is
known about the enzymes responsible for the degradation of
other proteoglycans.
Recent studies have demonstrated rapid catabolism and loss of
proteoglycans from tendon explants maintained in culture [109,
110]. Studies with antibodies to aggrecan, biglycan and decorin
showed that catabolites of aggrecan and decorin were present in
both young and mature tendon, consistent with constitutively
high levels of proteoglycan turnover [110]. There was no evidence
of MMP-mediated proteoglycan turnover, although aggrecan
turnover did not correlate with levels of mRNA expression for
ADAMTS-4 or ADAMTS-5. Currently little is known about the
factors that regulate aggrecanase activities in connective tissues.
The matrix in chronic tendinopathy
There have been relatively few biochemical studies of chronic
tendinopathy, and most have been of material collected at the end-
stage of the condition after tendon rupture. Studies of degenerate
supraspinatus tendons found a small but signiﬁcant decrease in the
total collagen content, and an increased proportion of type III
collagen relative to type I collagen [48]. Post-translational modi-
ﬁcation of the collagen network was also different compared with
age-matched normal tendons. Hydroxylysine and the mature
collagen cross-links (HP and LP) were signiﬁcantly increased, to a
much greater extent than expected given the increased collagen
type III content, which normally contains half the hydroxylysine
and HP content of collagen type I [61]. Similar changes have been
found in animal tendons in chronic tendinopathy [111] and after
acute injury induced by surgical trauma or collagenase injection
[112–115]. Although levels of hydroxylation and the HP cross-link
tend to diminish as healing proceeds, incomplete remodelling
commonly results in persistently high levels in scar tissue [116].
Other biochemical studies have shown an increase in hyaluronan
and various proteoglycans in degenerate tendons, as yet not fully
characterized [63, 111]. There are differences in the sugar moieties
expressed in ruptured Achilles tendons, as shown by changes in
lectin staining properties [117]. Glycoproteins such as tenascin-C
were increased in ruptured supraspinatus, with differences in the
isoforms expressed as well as small peptide fragments; this is
evidence for enzyme-mediated cleavage in the tissue [118].
Fibronectin immunostaining was signiﬁcantly increased in
ruptured tendon, and there was accumulation of necrotic tissue
and ﬁbrin [119]. These matrix changes are consistent with a wound
healing process occurring in the degenerate tendon, albeit with
impaired or incomplete remodelling, rather than any functional
adaptation. The available evidence generally supports the
hypothesis that accumulated micro-injuries result in a gradual
deterioration in the quality of the tendonmatrix. There is a gradual
transformation of the matrix, from organized type I collagen ﬁbrils
to a tissue consisting of randomly organized, small-diameter ﬁbrils
containing type I and type III collagen.
Matrix turnover in tendinopathy
Although some of the changes found in ruptured tendons may be
the result of rupture rather than the cause, there are reasons
to suspect that a change in collagen turnover precedes and
predisposes to tendon rupture. A study of the molecular age of the
collagen network by an analysis of pentosidine content demon-
strated greater levels of matrix turnover in supraspinatus tendons
compared with age-matched biceps brachii tendons [61] (Fig. 2).
Pentosidine did not accumulate in a linear fashion with age, and it
was estimated that up to 50% of the collagen in the supraspinatus
had been replaced over the individuals’ lifetime [61] (Fig. 2B).
Levels of pentosidine were substantially lower in ruptured tendons,
demonstrating that a greater proportion of the matrix collagen, up
to 90% of the total, was replaced in ruptured supraspinatus
tendons [61]. These data have since been supported by an analysis
of the racemization of the amino acid aspartate, another indicator
of the molecular age of the protein network [86]. Thus it appears
that a relatively high level of matrix remodelling is common in
tendons such as the supraspinatus, and that this process is linked to
the onset of degenerative pathology.
Increased collagen turnover in supraspinatus tendons was
associated with the increased expression and activity of several
members of the MMP family. In control supraspinatus tendons,
MMP-1, MMP-2 and MMP-3 activities were signiﬁcantly higher
compared with normal biceps brachii tendons, which showed little
or no collagen turnover [86]. In ruptured supraspinatus tendons,
there were increased levels of MMP-1 activity, reduced levels of
MMP-2 and MMP-3, and evidence of increased collagen
denaturation and turnover [86]. MMP-3 (stromelysin 1) is thought
to be a key regulatory enzyme in the control of matrix turnover,
and a decline in this enzyme may represent a failure in the normal
remodelling process. Thus, tendinopathy may result from a failure
to repair or adequately maintain the tendon matrix in response to
mechanical strain or repeated micro-trauma.
A study of synovial ﬂuids from the glenohumeral joint of
patients with rotator cuff pathology showed high levels of
expression of both MMP-1 and MMP-3 in patients with ruptured
tendons, with no change in the levels of TIMP-1, and the levels of
enzyme correlated with the size of tear [120]. GAG levels were also
higher in ﬂuids from massive tears compared with partial tears,
consistent with increased turnover of matrix proteoglycans [120].
Immunolocalization studies have shown MMP-1 expressed at the
edge of the tear in ruptured supraspinatus [121] and increased
expression in patellar tendinosis [122].
The importance of matrix turnover in tendon pathology was
also demonstrated in a molecular study of Achilles tendinopathy
using cDNA arrays [9]. Out of 265 genes that were analysed, 17
genes were up-regulated and 23 were down-regulated in degenerate
tissue samples. The absence of inﬂammation within the tendon was
conﬁrmed, and there were large increases in the expression of
matrix genes such as collagen type I and type III. The proteo-
glycans versican, biglycan and perlecan were increased, but there
was no change in decorin. Glycoproteins such as laminin, SPARC
(secreted protein acidic and rich in cysteine) and tenascin-C
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were also increased; the latter observation was consistent
with earlier biochemical studies [118]. In addition to matrix genes,
there were substantial changes in MMP expression. MMP-2,
MMP-3, MMP-14, MMP-16 and MMP-19 were all detected
in normal tendon. The greatest difference between normal and
pathological specimens was in the level of MMP-3 mRNA (also
reﬂected in the level of MMP-3 protein), which was absent or less
abundant in painful tendinopathy and ruptured tendon [9].
Expression of MMP-1 mRNA was not detected, either in normal
tendons or in chronic tendon lesions. BecauseMMP-1 andMMP-3
are normally regulated co-ordinately, the difference in expression is
an interesting observation that is yet to be explained. It is possible
thatMMP-3 activity is required for normal tendonmaintenance, at
least in highly stressed tendons, such as the supraspinatus and the
Achilles. The loss of MMP-3 activity in tendinopathy could
account for the increase in proteoglycan commonly found in
tendon lesions, as these are potential substrates for the enzyme.
However, more work is required to investigate the role of
other proteoglycan-degrading enzymes, such as the aggrecanases
(ADAMTS-1, 4 and 5), in tendon pathology.
The important role of MMPs in tendon pathology is further
supported by the side-effect proﬁle of two very different drug
compounds. First, a broad-spectrum inhibitor of matrix metallo-
proteinases was found to induce a painful tendinopathy in patients,
usually in the shoulders or hands [123]. Detailed studies are
required to determine which metalloproteinase activities are
implicated—whether an MMP, ADAM or ADAMTS enzyme.
Secondly, ﬂuoroquinolone antibiotics can also induce tendino-
pathy in some patients [124], and these drugs have recently been
shown to modulate MMP activity, at least in vitro [125, 126].
Studies on canine tenocytes showed a stimulation of caseinase
activity by canine tenocytes treated with ciproﬂoxacin. In studies of
human tenocytes we have shown a small stimulation of MMP-3
expression by ciproﬂoxacin [126]. In addition, pretreatment
with ciproﬂoxacin potentiated the stimulatory effect of IL-1 on
both MMP-1 and MMP-3 gene expression, and there was a
corresponding increase in synthesis of MMP-3 [126]. Because
ﬂuoroquinolones may also stimulate inﬂammatory pathways in or
around the tendon [127], the combined effect on tendon matrix
turnover may account for the onset of tendinopathy in some
patients.
Regulation of matrix turnover in tendinopathy
Despite many elegant hypotheses and in vitro studies, the factors
that induce pathological matrix remodelling in tendinopathy have
not been fully characterized. There is evidence that cell activities are
substantially altered in chronic tendon lesions. Cells in ruptured
tendons showed evidence of hypoxic changes [5], and levels of
lactate were increased in the peritendinous ﬂuid of patients with
Achilles tendinopathy, consistent with increased anaerobic activity
[128]. There was evidence of increased apoptosis in degenerate
rotator cuff tendons (almost 2.5 times higher than in controls),
implicating programmed cell death in the pathology [129].
Matrix interactions, insoluble deposits, mechanical strain and
locally released cytokines and signalling molecules (to name but a
few factors) may have a direct effect on tenocyte activity and the
expression of tendon matrix genes and enzymes. For example,
amyloid, calciﬁc deposits and breakdown products of proteins such
as tenascin-C have been shown to accumulate in degenerate tendon
[118, 130, 131]. Insoluble deposits are capable of increasing the
expression of enzyme activities and stimulating matrix turnover, at
least in vitro [132, 133]. Although inﬂammatory cytokines such as
IL-1 have not been detected in the tendon itself, there was greater
expression of IL-1 (and IL-1 receptor antagonist) in the synovium
of patients with perforating rotator cuff tears compared with those
with non-perforating tears, although the degree of shoulder pain
was inversely correlated with the levels of gene expression
[134, 135]. The inducible cyclooxygenase enzyme COX-2, a key
regulator in the pathway of prostaglandin synthesis, was
signiﬁcantly increased in patellar tendinosis, and there was
increased expression of transforming growth factor (TGF-1)
[136]. Increased cellularity at the site of the tendon lesion was
associated with the levels of expression of platelet-derived growth
factor (PDGF) receptor, and cells derived from lesions showed
increased rates of cell proliferation and a greater response to
PDGF compared with normal tendon cells [137]. Other mediators
of inﬂammation and vascular perfusion that are stimulated by
exercise, such as bradykinin, adenosine, IL-6, thromboxane and
prostaglandin E2, may also play a role [138] (see above).
Because substance P and other neuropeptides have been detected
in tendon and in ﬂuids collected from around painful tendons
[139–141], there is evidence for a ‘neurogenic’ hypothesis of
tendon overuse injury [142] (Fig. 3). Nerve endings and mast cells
may function as units to modulate tendon homeostasis and medi-
ate adaptive responses to mechanical strain. Excessive stimulation
as a result of overuse may result in pathological changes to the
tendon matrix. In support of this hypothesis, substance P has been
shown to modulate the expression of several (rabbit) tendonmatrix
FIG. 3. Neurogenic hypothesis of tendon ‘overuse’ injury. (A)
Nerve endings and mast cells in the matrix exist as functional
units in the tendon matrix. The release of neuropeptides such as
substance P (SP) and calcitonin gene-related peptide (CGRP)
stimulates the degranulation of mast cells, releasing a panoply of
agents which modulate a variety of cell activities in the matrix.
(B) Nerve and mast cell units function to modulate homeostatic
and adaptive responses in the normal tendon, although excessive
stimulation leads to tissue breakdown and degeneration.
Adapted from Hart et al. [142].
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genes and enzymes, including MMP-1, although the precise effects
were dependent on gender and hormonal status [143].
A study of TGF- expression in the Achilles showed that one
isoform (TGF-2) was predominant in the ﬁbrillar matrix of both
normal and pathological tendons [144]. Although TGF-2 was
increased in Achilles tendinopathy, the absence of one of the
TGF- signalling receptors (TGF-R1) was consistent with the
hypothesis that TGF- signalling was not actually taking place in
the tendon. Consequently, failure to control matrix degradation
may result from failure to up-regulate TIMPs in response to
TGF-. This observation suggests that the addition of growth
factors such as TGF- to facilitate tendon repair may be ineffective
in chronic tendinopathy. It is also consistent with the hypothesis
that the chronic nature of tendinopathy represents a failure to
regulate cell activities appropriately during repair or matrix
remodelling. Currently there are no therapies for tendinopathy that
speciﬁcally address this problem.
Animal models, gene knockouts and
tendon pathology
Studies of tendinopathy are hampered by the absence of suitable
animal models that mimic the chronic condition seen in humans.
Investigations of equine tendon lesions have demonstrated
accumulated damage after prolonged, high-intensity exercise,
with changes in the matrix similar to those described in human
tendinopathy [82, 145, 146]. Attempts to recreate tendon lesions
in smaller animals using exercise regimes have been generally less
successful [147]. Electrical stimulation of rabbit triceps surae
muscles to provoke kicking activity can induce changes in the
paratenon, and possibly also degeneration of the tendon matrix,
although these lesions have proved difﬁcult to reproduce [148,
149]. Various surgical procedures have been used in rabbit and
rodent models, as has the injection of enzymes (collagenase)
or inﬂammatory mediators such as prostaglandins [150–152].
Treatment of rodents with ﬂuoroquinolone antibiotics can
rapidly induce tendon lesions, with inﬂammation of the paratenon
preceding degenerative changes in the tendon matrix [153, 154].
Because these drugs can affect MMP expression by tendon
cells, this model may provide useful information about the disease
[126, 155].
The role of speciﬁc proteins has been investigated in gene-
knockout animal models. Mice deﬁcient in any one of the small
proteoglycans (decorin, biglycan, ﬁbromodulin or lumican)
manifest with smaller-diameter collagen ﬁbrils, joint laxity and
tendon weakness [156, 157]. Recently, inhibition of decorin
expression has been used to increase the diameter of collagen
ﬁbres in healing ligaments, and this approach may have some
promise in the treatment of tendon injury, improving the
mechanical properties of the scar tissue [158]. Mice with a mutated
collagen cleavage site that renders type I collagen resistant to
collagenase have thicker tendons than normal, and the tendon
insertion fails to migrate with bone growth, demonstrating the
importance of collagen turnover, at least during development [159,
160]. Mice lacking MMP-13, the rodent equivalent of MMP-1,
showed severely delayed wound healing in the skin, although the
effects on tendon healing have not been studied [161]. Future
studies combining models of tendon pathology with speciﬁc gene-
knockouts are likely to yield important information on the role of
speciﬁc matrix proteins and enzymes in tendon development and
disease.
Summary
The tendon matrix is ideally constructed to perform its major
function, the transfer of force frommuscle to bone. It is not a static
tissue, and the matrix will adapt according to the level, direction
and frequency of the applied load, a process of remodelling
mediated by the tendon ﬁbroblasts. The tendon matrix is
constantly remodelled throughout life, although higher rates of
turnover are found at sites exposed to high levels of strain,
compression or shear forces, such as the Achilles and the
supraspinatus. Matrix changes in tendon pathology could be
attributed to intrinsic factors, such as changes in cell activity with
age, or extrinsic factors, such as ‘overuse’, repetitive strain and
microtrauma. In degenerate tendon there is an increased rate of
matrix remodelling, leading to a qualitatively different and
mechanically less stable tendon, which is susceptible to damage.
Thus tendon degeneration may result from a failure to regulate
speciﬁc MMP activities in response to repeated injury or
mechanical strain. Whether tendon repair can be improved merits
further investigation of the factors controlling matrix remodelling
in tendon. These factors include mechanical strain, growth factors,
cytokines and neuropeptides, all of which have been implicated in
the control of tendon homeostasis, adaptation and repair.
The author has declared no conﬂicts of interest.
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